FDA Advisors Question Impact of OxyContin Improvements Due To Generics
Executive Summary
Purdue Pharma may be navigating a complicated regulatory path to extending its dominant market position for OxyContin
You may also be interested in...
Purdue Moves To Stave Off Branded, Generic Competitors To New OxyContin
Purdue Pharma is looking for assistance from FDA to help protect the company’s OxyContin franchise from both branded and generic competitors.
Purdue Moves To Stave Off Branded, Generic Competitors To New OxyContin
Purdue Pharma is looking for assistance from FDA to help protect the company’s OxyContin franchise from both branded and generic competitors.
FDA Okays Purdue's Newer OxyContin; Payors And Physicians Chew On Drug's Benefit
Purdue's reformulated OxyContin could face generics in 2013 unless FDA withdraws the initial NDA because of safety concerns.